SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
Pursuant to Section 13 or 15(d) of
the Securities Exchange Act of 1934
May 16, 2007
Date of Report (Date of earliest event reported)
(Exact name of registrant as specified in its charter)
(State or other
jurisdiction of incorporation)
162 Fifth Avenue, Suite 900
New York, NY
|(Address of principal executive offices)||(Zip Code)|
(Registrants telephone number, including area code)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):
¨ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
¨ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
¨ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
¨ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
Item 5.02 Departure of Directors or Principal Officers; Election of Directors; Appointment of Principal Officers
On May 16, 2007, Antigenics Inc. (the Company) and Roman Chicz, Sr. Vice-President, Research and Development, agreed that effective May 18, 2007 Mr. Chicz would cease to be an employee of the Company, and, subject to agreeing upon terms and conditions, Mr. Chicz would become a consultant to the Company for a period of six months. Mr. Chicz will receive severance compensation in connection with his departure.
Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
|Date: May 22, 2007||By:||/s/ Garo H. Armen, Ph.D|
Garo H. Armen, Ph.D.
Chairman and Chief Executive Officer